KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Evan Kidder, Nirav Dhanesha

Curr Opin Hematol 10.1097/MOH.0000000000000941

PMID42348666
PMCID-
DOI10.1097/MOH.0000000000000941
发表日期2026-06-25
AI 判定该论文不进入自动 KM 提取:This is a review article summarizing multiple clinical trials, not a report of a single Phase III randomized controlled trial. The record discusses several randomized studies but does not present original data from one specific Phase III trial; it is a review of existing evidence.
摘要

摘要

PURPOSE OF REVIEW: Factor XI (FXI) and its activated form, factor XIa (FXIa), have emerged as a leading novel anticoagulant target of the past decade. This review summarizes mechanistic and clinical data from 2023 through 2026 and proposes an indication-specific framework for FXIa inhibitor positioning. RECENT FINDINGS: Three large randomized studies diverged by indication. Abelacimab reduced major and clinically relevant nonmajor bleeding by 62% versus rivaroxaban in atrial fibrillation (AZALEA-TIMI 71). Asundexian was inferior to apixaban for stroke prevention in atrial fibrillation (OCEANIC-AF) yet reduced recurrent stroke after noncardioembolic events (OCEANIC-STROKE). Milvexian entered a three-trial phase 3 program. FXIa has been found to drive platelet and endothelial activation in inflammation-associated thrombosis, whereas the FXI zymogen has noncoagulation roles that include activation of bone morphogenetic protein 7-SMAD1/5 cardioprotection. A fifth drug class of allosteric FXI activation inhibitors was further characterized. SUMMARY: FXIa contribution to thrombus formation varies by anatomic site, flow conditions, and inflammatory phenotype. The clinical data support indication-specific positioning for cancer-associated thrombosis, secondary stroke prevention, and patients at high bleeding risk, but provide weaker support for broad substitution for direct oral anticoagulants.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。